O8Z Stock Overview
Develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sonoma Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.09 |
| 52 Week High | US$7.51 |
| 52 Week Low | US$2.60 |
| Beta | 1.38 |
| 1 Month Change | 0% |
| 3 Month Change | -0.24% |
| 1 Year Change | n/a |
| 3 Year Change | -95.88% |
| 5 Year Change | -96.14% |
| Change since IPO | -99.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| O8Z | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 0.5% |
| 1Y | n/a | -16.3% | 7.2% |
Return vs Industry: Insufficient data to determine how O8Z performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how O8Z performed against the German Market.
Price Volatility
| O8Z volatility | |
|---|---|
| O8Z Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: O8Z's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine O8Z's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10 | Amy Trombly | sonomapharma.com |
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
Sonoma Pharmaceuticals, Inc. Fundamentals Summary
| O8Z fundamental statistics | |
|---|---|
| Market cap | €3.39m |
| Earnings (TTM) | -€3.47m |
| Revenue (TTM) | €12.76m |
0.3x
P/S Ratio-1.0x
P/E RatioIs O8Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| O8Z income statement (TTM) | |
|---|---|
| Revenue | US$13.55m |
| Cost of Revenue | US$8.33m |
| Gross Profit | US$5.22m |
| Other Expenses | US$8.90m |
| Earnings | -US$3.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.75 |
| Gross Margin | 38.52% |
| Net Profit Margin | -27.21% |
| Debt/Equity Ratio | 1.5% |
How did O8Z perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/13 23:38 |
| End of Day Share Price | 2024/08/16 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sonoma Pharmaceuticals, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Robert Wasserman | Dawson James Securities |
| Jeffrey Cohen | Ladenburg Thalmann & Company |